Is Compounded Semaglutide the Same as Ozempic?

The short answer: No. Compounded semaglutide is NOT the same as Ozempic. It is NOT FDA-approved, has NOT undergone bioequivalence testing, and has NOT been shown to be equivalent to, or interchangeable with, Ozempic or Wegovy. While compounded semaglutide and Ozempic share the same active ingredient (semaglutide), sharing an active ingredient does not make two products equivalent. Only FDA-approved semaglutide products such as Ozempic and Wegovy have completed the clinical trials and FDA review that establish their labeled safety, effectiveness, and quality.

This article is an honest, plain-language explainer of how compounded semaglutide and Ozempic differ, why those differences matter, and what "same active ingredient" does and does not mean. It is for educational purposes only and is not medical advice.

Table of Contents

• The Short Answer: No, They Are Not the Same
• What Ozempic Actually Is
• What Compounded Semaglutide Is
• "Same Active Ingredient" Does Not Mean Equivalent
• Side-by-Side Comparison
• How and Why They Differ
• What FDA Approval Means (and What It Doesn't)
• "FDA-Registered Facility" Is Not FDA Approval
• What the Clinical Trial Data Applies To
• Important Safety Information
• Why Some People Consider Compounded Semaglutide
• Frequently Asked Questions

The Short Answer: No, They Are Not the Same

If you take only one thing from this article, take this: compounded semaglutide is not the same as Ozempic, is not equivalent to it, and is not interchangeable with it.

Ozempic is a specific, finished pharmaceutical product manufactured by Novo Nordisk and approved by the U.S. Food and Drug Administration (FDA). Compounded semaglutide is a custom preparation made by a compounding pharmacy. They are not the same product, they are not regulated the same way, and they have not been tested against each other to show they perform the same.

It is true that both contain semaglutide as the active ingredient. But two products can share an active ingredient and still differ in formulation, concentration, inactive ingredients, manufacturing controls, testing, and regulatory status. None of those differences are trivial, and none of them have been resolved by a head-to-head equivalence study for compounded versions. Compounded semaglutide has not undergone bioequivalence testing and has not been shown to be equivalent to Ozempic or Wegovy.

What Ozempic Actually Is

Ozempic is an FDA-approved prescription medication made by Novo Nordisk. Its active ingredient is semaglutide, a GLP-1 receptor agonist. Ozempic is FDA-approved to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of certain cardiovascular events in adults with type 2 diabetes and known heart disease. (Wegovy is a separate Novo Nordisk semaglutide product FDA-approved for chronic weight management.)

Because Ozempic is FDA-approved, the specific finished product — the exact formulation, concentration, delivery device (a pre-filled pen), and manufacturing process — has been reviewed by the FDA and is required to meet federal manufacturing and quality standards. The product you receive is the same product that was studied in clinical trials and reviewed by regulators.

What Compounded Semaglutide Is

Compounded semaglutide is a custom-prepared version of semaglutide made by a licensed compounding pharmacy for an individual patient based on a prescription, rather than mass-manufactured and FDA-approved as a finished product.

Compounding pharmacies obtain semaglutide as a raw active pharmaceutical ingredient (API) and combine it with other ingredients to prepare an injectable solution, typically supplied in vials. Compounded semaglutide is not FDA-approved. The FDA has not reviewed any compounded semaglutide preparation for safety, effectiveness, or quality, and the specific formulation a pharmacy prepares has not gone through the testing required of an FDA-approved drug.

This is a meaningful legal and regulatory distinction. It is also worth noting that semaglutide is no longer on the FDA drug shortage list (the shortage was resolved in 2025), so compounding of semaglutide today occurs under the patient-specific and other limited circumstances that compounding law allows — not on the basis of a shortage.

"Same Active Ingredient" Does Not Mean Equivalent

This is the heart of the confusion, so let's be precise. Compounded semaglutide and Ozempic share the same active ingredient (semaglutide), but sharing an active ingredient does not make two products equivalent, interchangeable, or therapeutically the same.

Equivalence is a specific, demonstrated thing. For a generic drug to be sold as equivalent to a brand-name drug, the manufacturer must prove bioequivalence — that it delivers the active ingredient to the body in the same amount and at the same rate, within tight statistical limits — and the FDA must review and approve that evidence. Compounded semaglutide has not gone through this process. There is no bioequivalence testing establishing that any compounded semaglutide performs the same as Ozempic.

So even though the molecule on the label is the same, you cannot assume the two products behave the same in the body. The formulation, the concentration, the purity, the inactive ingredients, and the manufacturing controls can all differ — and none of that has been demonstrated equivalent for a compounded version.

Side-by-Side Comparison

How and Why They Differ

Beyond regulatory status, there are several concrete ways the two can differ.

Formulation and Inactive Ingredients

Ozempic has a single, fixed formulation reviewed by the FDA. Compounded preparations can vary by pharmacy and may include different inactive ingredients (for example, different buffers, preservatives, or co-formulated substances). These differences are not trivial — they can affect stability and how the product behaves, and they have not been studied for equivalence.

Concentration and Presentation

Ozempic is delivered through a pre-filled pen designed and tested for its specific concentration. Compounded semaglutide is typically supplied in vials, and concentrations can vary between pharmacies and preparations. This is one reason the two are not interchangeable, and it is why dosing must be directed entirely by your prescribing clinician rather than carried over from one product to another.

Testing and Quality Controls

FDA-approved products are manufactured under federal good manufacturing practice requirements, with the finished product subject to FDA oversight. Compounded preparations are subject to pharmacy-level standards (such as applicable USP standards) rather than FDA approval of the finished medication. The level and type of testing can differ, and the FDA does not verify the safety, effectiveness, or quality of compounded medications.

What This Means Practically

Because of all of the above, you should not assume that a given amount of compounded semaglutide will act like the same labeled amount of Ozempic, and you should not switch between products or adjust anything on your own. Any decisions about which product to use, and any dosing, should be made by a licensed clinician who is evaluating and monitoring you.

What FDA Approval Means (and What It Doesn't)

FDA approval of a finished drug product means the agency has reviewed evidence that the specific product is safe and effective for its labeled uses, and that it is manufactured to consistent quality standards. Ozempic and Wegovy carry this approval.

Compounded semaglutide does not. The absence of FDA approval does not by itself mean a compounded preparation is unsafe — but it does mean the safety, effectiveness, and quality of that specific preparation have not been verified by the FDA, and that it has not been shown equivalent to the approved brand. That is a genuine difference a patient should understand, not gloss over.

"FDA-Registered Facility" Is Not FDA Approval

You may see compounded products described as being made in an "FDA-registered facility." It is important to understand what that phrase means. Facility registration is NOT FDA approval of the medication. A facility being registered with the FDA refers to the facility's regulatory listing — it does not mean the FDA has reviewed, approved, or verified the specific medication that facility prepares.

In other words, a registered facility can still produce a product that is not FDA-approved and not shown equivalent to Ozempic. Don't let "FDA-registered facility" be read as "FDA-approved medication." They are not the same thing.

What the Clinical Trial Data Applies To

The well-known clinical trial results for semaglutide — including the blood-sugar and weight-related outcomes you may have read about — come from studies of the FDA-approved branded products (Ozempic and Wegovy). Those results were generated using those specific, FDA-approved formulations under controlled study conditions.

Those figures should be attributed to the FDA-approved branded products. Results vary from person to person, are not guaranteed, and may not apply to compounded semaglutide, which was not the product studied. Compounded semaglutide has not been evaluated in those trials, and no specific weight-loss result is promised or guaranteed with any semaglutide product.

Important Safety Information

The FDA-approved semaglutide products (Ozempic and Wegovy) carry a Boxed Warning regarding the risk of thyroid C-cell tumors. Because compounded semaglutide is the same molecule, this thyroid C-cell risk is understood to apply to it as well, and the same contraindications should be observed. In rodent studies, semaglutide caused thyroid C-cell tumors; it is not known whether semaglutide causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Semaglutide is contraindicated in people with a personal or family history of MTC and in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your healthcare provider about your medical and family history before starting any semaglutide product.

Semaglutide can also cause other side effects, including gastrointestinal effects such as nausea, and more serious risks discussed in the FDA-approved labeling. Whether a semaglutide product is appropriate for you is a clinical decision that should be made with a licensed healthcare provider who evaluates and monitors you. For general information on side effects, see our guide on managing semaglutide side effects.

Why Some People Consider Compounded Semaglutide

People sometimes consider compounded semaglutide for reasons such as cost or access. That is understandable, and the point of this article is not to tell you what to choose — it is to make sure the choice is informed. None of those reasons change the core facts: compounded semaglutide is not FDA-approved, has not been bioequivalence-tested, and is not equivalent to or interchangeable with Ozempic.

If a licensed prescriber determines that a compounded preparation is appropriate for a specific patient, that determination must be patient-specific, clinician-directed, and documented — based on a valid prescription and the individual's clinical situation. Compounding is not a universal or automatic substitute for an FDA-approved product, and it should never be framed that way.

If you want to understand semaglutide more broadly before talking with a provider, see our complete guide to semaglutide, our overview of compounded semaglutide safety, and our comparison of oral semaglutide versus injection.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic?

No. Compounded semaglutide is not the same as Ozempic, is not equivalent to it, and is not interchangeable with it. They share the same active ingredient (semaglutide), but that does not make them equivalent. Compounded semaglutide is not FDA-approved and has not undergone bioequivalence testing.

If they have the same active ingredient, why aren't they equivalent?

Equivalence is something that has to be demonstrated through bioequivalence testing and FDA review — it isn't established just by sharing an active ingredient. Formulation, concentration, inactive ingredients, and manufacturing controls can differ, and none of that has been shown to be equivalent for compounded semaglutide.

Is compounded semaglutide FDA-approved?

No. The FDA has not approved any compounded semaglutide preparation. The FDA does not verify the safety, effectiveness, or quality of compounded medications.

Does the Ozempic clinical trial data apply to compounded semaglutide?

No. Those results come from studies of the FDA-approved branded products. Results vary, are not guaranteed, and may not apply to compounded semaglutide, which was not the product studied.

Can I expect the same results from compounded semaglutide that I'd get from Ozempic?

There is no guarantee of any specific result with any semaglutide product, and compounded semaglutide has not been shown to perform the same as Ozempic. Individual results vary, and any expectations should be discussed with your clinician.

Does "FDA-registered facility" mean the compounded medication is FDA-approved?

No. Facility registration is not FDA approval of the medication. A facility can be registered with the FDA while producing a product that is not FDA-approved and not shown equivalent to Ozempic.

Is compounded semaglutide being made because of a shortage?

No. Semaglutide is no longer on the FDA drug shortage list — the shortage was resolved in 2025. Compounding of semaglutide today occurs under the patient-specific and other limited circumstances that compounding law allows, not on the basis of a shortage.

Can I switch between Ozempic and compounded semaglutide on my own?

No. The two are not interchangeable, and concentrations and formulations can differ. Any product choice or dosing decision should be made and directed by a licensed clinician who is evaluating and monitoring you.

Is there a boxed warning I should know about?

Yes. The FDA-approved semaglutide products (Ozempic and Wegovy) carry a Boxed Warning about the risk of thyroid C-cell tumors and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Because compounded semaglutide is the same molecule, the same thyroid C-cell risk and contraindications should be observed. Discuss your history with your provider.

Related Articles

• Complete Guide to Semaglutide
• Is Compounded Semaglutide Safe? What You Should Know
• Managing Semaglutide Side Effects
• Oral Semaglutide vs. Injection

Medical Disclaimer

This article is for educational purposes only and is not medical advice. Compounded semaglutide is NOT FDA-approved and has NOT been shown to be equivalent to or interchangeable with Ozempic or Wegovy. The FDA does not verify the safety, effectiveness, or quality of compounded medications. No specific outcome or result is promised or guaranteed. Always talk with a licensed healthcare provider about your individual medical history and whether any treatment is appropriate for you. If you are interested in a clinician-directed program, you can learn more about our compounded semaglutide program or browse our weight loss treatments.